<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265443</url>
  </required_header>
  <id_info>
    <org_study_id>POSTPCI_NHPRs20200206</org_study_id>
    <nct_id>NCT04265443</nct_id>
  </id_info>
  <brief_title>Prognostic Perspective of Invasive Hyperemic and Non-Hyperemic Physiologic Indices Measured After Percutaneous Coronary Intervention</brief_title>
  <acronym>PERSPECTIVEPCI</acronym>
  <official_title>Prognostic Perspective of Invasive Hyperemic and Non-Hyperemic Physiologic Indices Measured After Percutaneous Coronary Intervention (PERSPECTIVE-PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sejong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chosun University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary physiologic assessments by the pressure-derived fractional flow reserve (FFR) have&#xD;
      become standard methods for identifying hemodynamic deprivation in coronary arterial stenosis&#xD;
      for evidence-based percutaneous coronary intervention (PCI). Invasive physiologic&#xD;
      indices-guidance enables on-site real time assessment for functional significance of&#xD;
      epicardial coronary stenosis and the use of those indices has shown to be effective to guide&#xD;
      treatment decision. Several studies further support the role of post-PCI FFR measurement as a&#xD;
      functional marker of residual disease after PCI and prognostic indicator of patients.&#xD;
      Although optimal cut-off values of post-PCI FFR varied across studies, an inverse&#xD;
      relationship between post-PCI FFR and the risk of future clinical events have been reported&#xD;
      consistently.&#xD;
&#xD;
      Recently, non-hyperemic pressure ratios (NHPRs) have been introduced in clinical practice.&#xD;
      Although there are several different NHPRs, previous studies consistently indicated that&#xD;
      those NHPRs shares similar diagnostic performance and prognostic implications. Nevertheless,&#xD;
      few reports were available for clinical relevance of NHPRs in evaluation of post-PCI status.&#xD;
&#xD;
      In this context, we will evaluate the physiologic characteristics and prognostic implication&#xD;
      of post-PCI NHPRs and compare with those of post-PCI FFR in patients who underwent&#xD;
      angiographically successful PCI with 2nd generation drug-eluting stent implantation (DES).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who diagnosed significant coronary artery disease and treated by 2nd generation DES&#xD;
      with post-PCI physiologic evaluation would be enrolled.&#xD;
&#xD;
      Invasive physiologic assessment including recording of resting pressure trecing would be&#xD;
      required at the baseline and at the end of index PCI procedure. PCI procedure would be&#xD;
      performed upon local routine. Any available 2nd generation DES could be used. Web-based&#xD;
      electronic-case record form (CRF) system will be used for collecting data. All data will be&#xD;
      handled and analyzed by blind fashion at independent core lab. 2-year clinical outcome after&#xD;
      index procedure will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>2 years after index procedure</time_frame>
    <description>a composite of cardiac death, clinically-driven target vessel-related myocardial infarction, and clinically-driven target vessel revascularization. The target vessel will be defined as the treated vessel with 2nd generation DES which was assessed by post stent fractional flow reserve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>independent predictors for target-vessel failure</measure>
    <time_frame>2 years after index procedure</time_frame>
    <description>independent predictors for target-vessel failure by univariate and multivariate analysis will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delta FFR per unit time</measure>
    <time_frame>At the time of index procedure</time_frame>
    <description>delta FFR per unit time in pre-PCI pullback recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative percent increase of physiologic indices</measure>
    <time_frame>At the time of index procedure</time_frame>
    <description>Percent increase of FFR or non-hyperemic pressure ratios</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">588</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Post PCI state</arm_group_label>
    <description>The study population of this study underwent percutaneous coronary intervention(PCI) with 2nd generation drug-eluting stent (DES) and measured invasive physiologic indices after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>PCI was performed using 2nd generation DES</description>
    <arm_group_label>Post PCI state</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who diagnosed obstructive coronary artery disease and treated by DES with invasive&#xD;
        physiologic evaluation at the index procedure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any patient meets eligible criteria who underwent PCI with DES followed by invasive&#xD;
             physiologic assessment at the index procedure&#xD;
&#xD;
          -  available both post-PCI resting pressure tracing and FFR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  culprit vessel of acute coronary syndrome&#xD;
&#xD;
          -  failed achieving TIMI 3 flow at the end of PCI&#xD;
&#xD;
          -  left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  graft vessel&#xD;
&#xD;
          -  collateral feeder&#xD;
&#xD;
          -  in-stent restenosis&#xD;
&#xD;
          -  primary myocardial or valvular heart disease&#xD;
&#xD;
          -  in patient whose life expectancy less than 2 years&#xD;
&#xD;
          -  visible thrombus of target vessel segment&#xD;
&#xD;
          -  unmeasured post-PCI resting pressure tracings&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Myung Lee, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan Medical Center</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joo Myung Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>fractional flow reserve</keyword>
  <keyword>non-hyperemic pressure ratio</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>prognosis</keyword>
  <keyword>myocardial ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>De-identified patient data will be shared upon reasonable request after discussion in executive committee.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

